STAR Infigratinib vs Gem/Cis Cholangio
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More
Phase: III
PI/II Cholangiocarcinoma CX-4945 w Gem
A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001) Read More
Phase: II
Sitravatinib + Nivo Adv/Met Urothelial
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Ph 2 rib + non-ster AIs HR+ HER2- aBC
A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207) Read More
Phase: II
Ph3 Pembro HR+/HER2- BC
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756) Read More
Phase: III
FLEX Registry: Evaluate New Gene Express
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph3b 1L CLL debulk combo
A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788) Read More
Phase: III
Ph3b Venetoclax AML
A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072) Read More
Phase: III
Ph1/2 AGEN1884 Adv Refractory cancer
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01) Read More
Phase: I/II
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Ph 1/1b Immunotherapy Combo in NSCLC
(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Read More
Phase: I
Ph 3 Sit+Nivo vs. Docetaxel NSCLC
516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy Read More
Phase: III
Ph2 MGCDs+Nivo NSCLC
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500) Read More
Phase: II
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1) Read More
Phase: I
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Ph3 Adj canakinumab NSCLC
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301) Read More
Phase: III
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789) Read More
Phase: III
Atezo Rollover for GNE & Roche
BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study Read More
Phase: II/III
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More
Phase: III
Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC
CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Read More
Phase: III/IV
Ph3 Rituximab +/- Ibrutinib tx-naive FL
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA Read More
Phase: III
STAR BV in older pts w/1L cHL or PTCL
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above Read More
Phase: II
Ph2 BGB-3111 R/R MZL
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma (BGB-3111-214) Read More
Phase: II
Ph2 R/R MCL (CITADEL-205)
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205 Read More
Phase: II
TGR-1202 +/- Ublituximab in NHL
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205) Read More
Phase: II
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Phase: III
Ph1b/2 R/R FL, R/R DLBCL
A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834) Read More
Phase: I/II
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
STAR Ph2 Itacitinib +/- Ruxo in MF
INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Read More
Phase: II
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph1/2 INCB001158 + SC Dara vs Dara SC MM
A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206) Read More
Phase: I/II
Ph4 Ixazomib+Lena & Dex MM (MM-6)
C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV) Read More
Phase: IV
Ph3 TSR-042, Niraparib Ovarian FIRST
3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER Read More
Phase: III
Ph 1b FIH XMT-1536 Solid Tumor NaPi2b
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1) Read More
Phase: I
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
PANOVA-3: 1L Gemcit + nab-pac pancreatic
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read More
Phase: III
Ph1 Solid tumors, RCC, mCRPC
(AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies Read More
Phase: I
STAR Abirat+pred +/- abemaciclib mCRPC
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More
Phase: II
STAR Ph2 Rucaparib mCRPC (TRITON 2)
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 Read More
Phase: II
STAR Rucaparib v PhysC mCRPC (TRITON3)
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More
Phase: III
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
Ph1 Solid tumors, RCC, mCRPC
(AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies Read More
Phase: I
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph1 Solid tumors, RCC, mCRPC
(AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies Read More
Phase: I
STAR Ph2 Pemigatinib Solids FGFR
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More
Phase: II
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors Read More
Phase: I
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Ph1 FIH TP-1287 Solid tumor
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101) Read More
Phase: I
Ph1 MSB0011359C Solid Tumors
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 Read More
Phase: I
STAR Ph3 FGFR erdafitinib urothelial
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More
Phase: III
Phase 1/2a BMS-986253 + Nivo
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More
Phase: I/II
Sitravatinib + Nivo Adv/Met Urothelial
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II